POLE and POLD1 Proofreading Mutations: Ultramutated Tumours

What Proofreading Does

During replication, DNA polymerase epsilon (POLE) and delta (POLD1) synthesise the leading and lagging strands. When a wrong base is added, the polymerase can shift the primer terminus into its 3'-to-5' exonuclease site and excise the error before continuing. This built-in correction reduces the replication error rate by roughly two orders of magnitude.

Exonuclease-domain missense changes such as POLE P286R or V411L, and POLD1 S478N, impair that correction without stopping synthesis. Errors accumulate genome-wide, producing tumours often described as 'ultramutated' — mutation counts well above those of mismatch-repair-deficient tumours.

A Distinct Mutational Signature

Proofreading loss leaves a characteristic pattern: a strong excess of C>A changes at TCT sites and C>T changes at TCG sites. This signature is detectable by genome or exome analysis and helps distinguish a genuine driver POLE alteration from an incidental exonuclease-domain variant of uncertain significance.

Because a passenger POLE variant outside the exonuclease domain does not produce this pattern, the reported variant location and any signature analysis should be read together rather than treating the gene name alone as informative.

Germline Versus Somatic Findings

Germline exonuclease-domain variants cause polymerase-proofreading-associated polyposis, a rare dominant condition linked to colorectal polyps and cancer and to endometrial and other tumours. A germline result therefore has implications for relatives and warrants genetics assessment.

A somatic-only POLE driver, common in a subset of endometrial and colorectal cancers, describes the tumour and does not by itself indicate an inherited condition. Distinguishing the two usually requires paired normal tissue testing.

Why the Distinction Matters for Interpretation

Ultramutated tumours generate many predicted neoantigens, and POLE-driver endometrial cancers are frequently discussed as a favourable molecular subgroup. That population-level observation is not an individual treatment instruction, and trial and regulatory context still applies.

TMB values from targeted panels can be unreliable at the extreme high end, so an ultramutated result may need confirmation with a broader assay and correlation with the mutational signature.

How an Ultramutated Result Is Used

In endometrial cancer, a confirmed pathogenic POLE exonuclease-domain mutation defines one of four molecular subgroups and is consistently linked to excellent outcomes, to the point that de-escalating adjuvant treatment is being studied for early-stage POLE-mutant disease. That is a research direction rather than settled practice, and it applies specifically to genuine exonuclease-domain drivers, not to any POLE variant.

Across tumour types, the very high neoantigen load of proofreading-deficient cancers is why they are discussed alongside immune-checkpoint blockade, and some have responded even where standard tumour-mutational-burden thresholds were not clearly met. The link between mechanism and immunogenicity is developed in the neoantigen and tumour-mutational-burden guides.

Key Takeaways

• ·POLE and POLD1 proofreading loss produces very high, genome-wide mutation counts.
• ·The exonuclease-domain location of the variant and its mutational signature guide interpretation.
• ·Germline and somatic POLE findings answer different questions and may need paired normal testing.